Biblio
“Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
,